232 related articles for article (PubMed ID: 11146550)
1. Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53.
Cui XS; Donehower LA
Oncogene; 2000 Dec; 19(52):5988-96. PubMed ID: 11146550
[TBL] [Abstract][Full Text] [Related]
2. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha.
Bocchinfuso WP; Hively WP; Couse JF; Varmus HE; Korach KS
Cancer Res; 1999 Apr; 59(8):1869-76. PubMed ID: 10213494
[TBL] [Abstract][Full Text] [Related]
3. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis.
Jones JM; Attardi L; Godley LA; Laucirica R; Medina D; Jacks T; Varmus HE; Donehower LA
Cell Growth Differ; 1997 Aug; 8(8):829-38. PubMed ID: 9269892
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.
Brodie SG; Xu X; Li C; Kuo A; Leder P; Deng CX
Oncogene; 2001 Mar; 20(12):1445-54. PubMed ID: 11313888
[TBL] [Abstract][Full Text] [Related]
5. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
6. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
Hollmann CA; Kittrell FS; Medina D; Butel JS
Oncogene; 2001 Nov; 20(52):7645-57. PubMed ID: 11753642
[TBL] [Abstract][Full Text] [Related]
7. Different gene-expression profiles for the poorly differentiated carcinoma and the highly differentiated papillary adenocarcinoma in mammary glands support distinct metabolic pathways.
Eilon T; Barash I
BMC Cancer; 2008 Sep; 8():270. PubMed ID: 18811984
[TBL] [Abstract][Full Text] [Related]
8. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Brodie SG; Xu X; Qiao W; Li WM; Cao L; Deng CX
Oncogene; 2001 Nov; 20(51):7514-23. PubMed ID: 11709723
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
10. beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland.
Michaelson JS; Leder P
Oncogene; 2001 Aug; 20(37):5093-9. PubMed ID: 11526497
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands.
Klopfleisch R; Gruber AD
Res Vet Sci; 2009 Aug; 87(1):91-6. PubMed ID: 19185891
[TBL] [Abstract][Full Text] [Related]
12. Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis.
Choi HR; Tucker SA; Huang Z; Gillenwater AM; Luna MA; Batsakis JG; El-Naggar AK
Int J Oncol; 2003 Feb; 22(2):409-14. PubMed ID: 12527941
[TBL] [Abstract][Full Text] [Related]
13. Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model.
Jones JM; Cui XS; Medina D; Donehower LA
Cell Growth Differ; 1999 Apr; 10(4):213-22. PubMed ID: 10319991
[TBL] [Abstract][Full Text] [Related]
14. Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor.
Wang Y; Hu L; Yao R; Wang M; Crist KA; Grubbs CJ; Johanning GL; Lubet RA; You M
Oncogene; 2001 Nov; 20(53):7710-21. PubMed ID: 11753649
[TBL] [Abstract][Full Text] [Related]
15. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model.
Adnane J; Jackson RJ; Nicosia SV; Cantor AB; Pledger WJ; Sebti SM
Oncogene; 2000 Nov; 19(47):5338-47. PubMed ID: 11103935
[TBL] [Abstract][Full Text] [Related]
16. Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice.
Gordon J; Del Valle L; Otte J; Khalili K
Oncogene; 2000 Oct; 19(42):4840-6. PubMed ID: 11039901
[TBL] [Abstract][Full Text] [Related]
17. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool.
Luo JL; Yang Q; Tong WM; Hergenhahn M; Wang ZQ; Hollstein M
Oncogene; 2001 Jan; 20(3):320-8. PubMed ID: 11313961
[TBL] [Abstract][Full Text] [Related]
18. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of human cyclin G1 and G2: DNA damage inducible genes.
Bates S; Rowan S; Vousden KH
Oncogene; 1996 Sep; 13(5):1103-9. PubMed ID: 8806701
[TBL] [Abstract][Full Text] [Related]
20. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
